Search
Tools content (print, share, increase/decrease text size):
-
Size
Middle area:Press releases 2012Press releases are intended to journalists, analysts and investors. Merial to Acquire Animal Health Division of Dosch Pharmaceuticals in IndiaDecember 20, 2012 Sanofi President, Global Operations, to retireDecember 18, 2012 Amended Accounting Standard on Employee Benefits (IAS19R) applicable as from January 1, 2013December 18, 2012 Genzyme and Isis Provide Update on CHMP Opinion on KYNAMRO™ (mipomersen)December 14, 2012 Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary EndpointDecember 09, 2012 Sanofi Compounds to be Featured in 178 Abstracts at American Society of Hematology Annual MeetingDecember 03, 2012 Sanofi launches Awareness Campaign for Air France passengers on the Risks of Counterfeit MedicinesNovember 30, 2012 Sanofi Ranks Third on the Access to Medicine Foundation’s 2012 ATM IndexNovember 28, 2012 Sanofi Donates $500,000 to Hurricane Sandy Immediate and Long-Term Relief EffortsNovember 19, 2012 Sanofi Receives Positive CHMP Opinion in the European Union for Once-Daily Lyxumia® (lixisenatide)November 16, 2012 ZALTRAP® (aflibercept) Receives CHMP Positive Opinion in the European Union for Previously Treated Metastatic Colorectal CancerNovember 16, 2012 Sanofi Appoints Dr. Gary J. Nabel as Chief Scientific OfficerNovember 14, 2012 Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with DiabetesNovember 14, 2012 Sanofi and Institut Pasteur Honor Innovation in Biomedical Research with the Sanofi-Institut Pasteur 2012 AwardsNovember 13, 2012 Sanofi successfully prices EUR 750 million bond issueNovember 07, 2012 Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for HypercholesterolemiaNovember 05, 2012 Genzyme Announces Publication of LEMTRADA (alemtuzumab) Pivotal Studies in The LancetOctober 31, 2012 Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of MedicineOctober 31, 2012 Q3 2012 Business EPS reflects patent expirations. Growth Platforms reached over 70% of salesOctober 25, 2012 FDA Advisory Committee Recommends KYNAMRO™ for Homozygous Familial HypercholesterolemiaOctober 18, 2012 Genzyme Presents Second Phase III Study of Once-daily Oral AUBAGIO® (teriflunomide) Confirming Significant Impact on DisabilityOctober 12, 2012 Sanofi to Launch State-of-the Art, Reusable Insulin Pen AllStar™ in IndiaOctober 09, 2012 Genzyme to Present New Data from AUBAGIO and LEMTRADA Clinical Development Programs at ECTRIMSOctober 09, 2012 Sanofi Announces Final Results of its Modified Dutch Auction Tender Offer for its Outstanding Contingent Value RightsOctober 08, 2012 Journal of Clinical Oncology Publishes Phase III Results of ZALTRAP® (aflibercept) VELOUR Study in Previously Treated Metastatic Colorectal CancerOctober 08, 2012 New data from ORIGIN Shows Lantus® use is about 3 times more likely to achieve and sustain target HbA1c vs. standard care over 5 years in the study populationOctober 05, 2012 Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance AgreementOctober 03, 2012 Sanofi to Acquire Genfar S.A., a Leader in Pharmaceutical Medicines in ColombiaOctober 02, 2012 Lyxumia® (lixisenatide) in Combination with Basal Insulin plus Oral Anti-Diabetics Significantly Improved Glycemic ControlOctober 02, 2012 Genzyme Phase 3 Study of Oral Compound Eliglustat Tartrate for Gaucher Disease Meets Primary EndpointOctober 02, 2012 Sanofi appoints Dr. Paul Chew, Chief Medical Officer and Head of Global Medical AffairsOctober 01, 2012 EASD Abstracts Highlight Sanofi Commitment to Advancing Therapeutic Solutions in Diabetes CareSeptember 26, 2012 Sanofi provides information on the adaptation of its activities in France through 2015September 25, 2012 Sanofi and TB Alliance Announce Collaboration to Accelerate New Treatments Against TuberculosisSeptember 20, 2012 FDA Approves Genzyme’s AUBAGIO® (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Multiple SclerosisSeptember 12, 2012 Sanofi Pasteur Announces Publication in The Lancet of World's First Efficacy Results for its Dengue Vaccine CandidateSeptember 11, 2012 Sanofi Launches Modified Dutch Auction Tender Offer to Purchase up to 86,766,040 of its Outstanding Contingent Value RightsSeptember 04, 2012 Genzyme Provides Update on U.S. LEMTRADA™ FilingAugust 27, 2012 Sanofi Announces FDA Approval for Auvi-Q™, First Voice-guided Epinephrine Auto-injector for Patients with Life-threatening AllergiesAugust 13, 2012 U.S. FDA Approves ZALTRAP® (ziv-aflibercept) after Priority Review for Previously Treated Metastatic Colorectal CancerAugust 03, 2012 Availability Online of the Group’s Half-Year Financial Report for 2012July 27, 2012 As expected, Q2 2012 Business EPS impacted by the loss of exclusivity of Plavix® and Avapro® in the U.S.July 26, 2012 Sanofi Pasteur’s Dengue Vaccine Demonstrates Proof of EfficacyJuly 25, 2012 Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program with LDL Cholesterol-Lowering PCSK9 AntibodyJuly 20, 2012 Sanofi to divest its stake in the Yves Rocher GroupJuly 04, 2012 Sanofi Pasteur’s 6-in-1 Pediatric Vaccine Hexaxim™ Receives Positive Opinion from European Medicines AgencyJune 22, 2012 Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetesJune 19, 2012 Sanofi Voted Leading Pan-European Quoted Company for Investor Relations in the 2012 Thomson Reuters Extel SurveyJune 13, 2012 Genzyme Submits Applications to FDA and EMA for Approval of LEMTRADA™ (alemtuzumab) for Multiple SclerosisJune 12, 2012 New Epidemiological Data Provide Additional Safety Evidence for Lantus®June 11, 2012 Sanofi Announces Results of ORIGIN, the World’s Longest and Largest Randomized Clinical Trial in Pre- and Early DiabetesJune 11, 2012 Sanofi Submits Application for Regulatory Approval for Lyxumia® (lixisenatide) for the Treatment of Type 2 Diabetes in JapanJune 11, 2012 Lyxumia® (lixisenatide) in Combination with Basal Insulin plus Oral Anti-Diabetics Significantly Reduced HbA1c and Post-Prandial GlucoseJune 09, 2012 Lantus® Initiation after Metformin Achieved Superior Glycemic Control versus Sitagliptin in Type 2 DiabetesJune 09, 2012 Genzyme Reports Positive Top-Line Results of TOWER, a Pivotal Phase III Trial for AUBAGIO™ (teriflunomide) in Relapsing Multiple SclerosisJune 01, 2012 Sanofi Inaugurates Lantus® SoloSTAR® Pen Assembly Plant in its Beijing FacilityMay 28, 2012 Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The LancetMay 26, 2012 ASCO Abstracts Highlight Late-stage Sanofi Oncology PipelineMay 17, 2012 Combined General Shareholder Meeting of May 4, 2012May 04, 2012 Genzyme Announces Regulatory Approvals of Expanded Waterford, Ireland Manufacturing PlantMay 03, 2012 Japan Chooses Sanofi Pasteur for First Enhanced Inactivated Polio VaccineApril 27, 2012 Strong performance in Q1 2012 including Genzyme contributionApril 27, 2012 Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada™ (Alemtuzumab) Compared With Rebif® in Phase lll TrialApril 24, 2012 Genzyme Demonstrates Depth of MS Pipeline at AAN with Results from Multiple Sclerosis Phase lll TrialsApril 20, 2012 Sanofi and Michael J. Fox Foundation Collaborate on Potential New Treatment for Parkinson’s DiseaseApril 19, 2012 Sanofi and Regeneron Announce Regulatory and Clinical Update for Zaltrap® (afliberceptApril 05, 2012 Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 AntibodyMarch 26, 2012 Sanofi to Acquire Pluromed, Inc., Expanding its Presence in BiosurgeryMarch 16, 2012 Filing of the 2011 U.S. Form 20-F and French “Document de Référence” Containing the Annual Financial ReportMarch 07, 2012 Composition of Sanofi’s Board of DirectorsMarch 05, 2012 Sanofi appoints Jean-Luc Lowinski, Senior Vice President, Asia RegionMarch 02, 2012 Genzyme Begins Shipping Fabrazyme from Newly Approved Framingham Manufacturing PlantMarch 01, 2012 Sanofi and the Institut Pasteur Create Four Prestigious Awards to Support Innovative Biomedical ResearchFebruary 27, 2012 2011 Results Benefit from Genzyme Acquisition. Net Sales and Business EPS up 9.2% in Q4February 08, 2012 Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with ApotexFebruary 08, 2012 Sanofi Commits to Eliminate or Control Five Neglected Tropical DiseasesJanuary 30, 2012 Genzyme Announces FDA Approval of Framingham Manufacturing PlantJanuary 24, 2012 Brazil Introduces Inactivated Polio Vaccine in National Immunization Program with Sanofi Pasteur VaccineJanuary 18, 2012 Genzyme Announces European Approval of Framingham Manufacturing PlantJanuary 18, 2012 Sanofi and Venture Capital Firms, Third Rock Ventures and Greylock Partners, Jointly Launch Warp Drive Bio, a Biotechnology Company Combining Innovative Genomics Technologies for Natural Products Drug DiscoveryJanuary 10, 2012 |
Tools menu:
© Sanofi 2004-2013 - All rights reserved - Update: January 28, 2013
